Free shipping on all orders over $ 500

Sparsentan (RE-021)

Cat. No. M20689

All AbMole products are for research use only, cannot be used for human consumption.

Sparsentan (RE-021) Structure
Synonym:

PS-433540; RE-021; DARA-a; BMS-346567

Size Price Availability Quantity
5mg USD 65  USD65 In stock
10mg USD 105  USD105 In stock
25mg USD 210  USD210 In stock
50mg USD 330  USD330 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Sparsentan (PS-433540, RE-021, DARA) is a first-in-class, orally active, high-affinity dual antagonist of the endothelin type A receptor (ETA) and Angiotensin II type 1 (AT1) receptor, with Ki values of 9.3 and 0.8 nM, respectively. Sparsentan dose dependently antagonizes the angiotensin II-induced pressor response with an ED50 value of 0.8 µmol/kg iv and 3.6 µmol/kg po. Sparsentan also shows efficacious and long acting in the big ET-1-induced pressor model.

Sparsentan causes a significant lowering of blood pressure at the lowest dose tested (10 µmol/kg/day) in spontaneously hypertensive rats. Sparsentan shows good oral bioavailability in rats, dogs, and monkeys, averaging 40%, 86%, and 21% F, respectively. At 100 µmol/kg/day, Sparsentan reduces the blood pressure from 170 to less than 100 mmHg during the course of the compound’s pharmacokinetic duration. Sparsentan at 100 µmol/kg/day essentially converts the spontaneously hypertensive rats into normotensive rats during the course of its pharmacokinetic duration.

Chemical Information
Molecular Weight 592.75
Formula C32H40N4O5S
CAS Number 254740-64-2
Solubility (25°C) DMSO 90 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Efren Chavez, et al. Front Med (Lausanne). Novel Therapies for Alport Syndrome

[2] Isaac D Liu, et al. Cochrane Database Syst Rev. Interventions for idiopathic steroid-resistant nephrotic syndrome in children

[3] Elisabeth M Hodson, et al. Cochrane Database Syst Rev. Interventions for focal segmental glomerulosclerosis in adults

[4] Liang Li, et al. Mol Ther. Targeting tissue-resident memory CD8+ T cells in the kidney is a potential therapeutic strategy to ameliorate podocyte injury and glomerulosclerosis

Related Endothelin Receptor Products
Zibotentan

Zibotentan (ZD4054) is a more selective and specific endothelin-A receptor (ETAR) antagonist with an IC50 value of 21 nM.

Ambrisentan

Ambrisentan is an orally active, highly selective antagonist of the endothelin-1 type A receptor.

Sitaxsentan sodium

Sitaxsentan (TBC-11251) is an orally active, highly selective antagonist of endothelin A receptors.

Macitentan

Macitentan is an orally-active, tissue-targeting dual ET receptor antagonist.

Bosentan Hydrate

Bosentan is an endothelin (ET) receptors antagonist for ET-A and ET-B with Ki of 4.7 nM and 95 nM, respectively.

  Catalog
Abmole Inhibitor Catalog




Keywords: Sparsentan (RE-021), PS-433540; RE-021; DARA-a; BMS-346567 supplier, Endothelin Receptor, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.